Last reviewed · How we verify
Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy
Approved treatments
- Palazestrant · Pfizer Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy patent landscape — cliff calendar, originator estates, attackable patents
- Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy treatment landscape brief
- Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy treatment updates RSS
Frequently asked questions about Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy
What drugs treat Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy?
Tracked treatments include Palazestrant.
What is the treatment for Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy?
Standard treatment for Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy includes Palazestrant. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy patent cliff · Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy CI report
- Treatment: Palazestrant · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing